Related Experiment Videos
Therapeutic management of dilated cardiomyopathy
1Third Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Insights
Dilated cardiomyopathy (DCM) treatment focuses on managing symptoms and preventing further heart dysfunction. Angiotensin converting enzyme (ACE) inhibitors and beta-blockers are key in improving outcomes for DCM patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Dilated cardiomyopathy (DCM) treatment is largely symptomatic due to unidentified specific etiologies.
- Despite challenges, recent advancements in pharmacotherapy have improved DCM patient outcomes.
Purpose of the Study:
- To outline an aggressive therapeutic strategy for preventing ventricular dysfunction progression in DCM.
- To highlight the essential role of specific drug classes in managing DCM.
Main Methods:
- Review of current therapeutic approaches for dilated cardiomyopathy.
- Emphasis on the sequential use of vasodilators (ACE inhibitors), digitalis, diuretics, and beta-blockers.
- Consideration of inotropic agents and mechanical assist devices for refractory cases.
Main Results:
- Angiotensin converting enzyme (ACE) inhibitors and beta-blockers have significantly improved DCM treatment.
- Vasodilators, particularly ACE inhibitors, are essential for managing DCM.
- Diuretics and digitalis are used adjunctively for symptom control and heart failure management.
Conclusions:
- Aggressive management to prevent ventricular dysfunction is crucial in DCM due to poor prognosis.
- A stepwise pharmacological approach, including ACE inhibitors and beta-blockers, is recommended.
- Heart transplantation remains an option for end-stage DCM unresponsive to maximal medical therapy.
Abstract:
The therapeutic approach to dilated cardiomyopathy (DCM) still remains nonspecific and symptomatic, since no specific etiology is identified. Nevertheless, the recent introduction of angiotensin converting enzyme (ACE) inhibitors and beta-blockers greatly improved the treatment of DCM. The poor prognosis of patients with DCM encourages maximal aggressive attempts to prevent progression of ventricular dysfunction rather than to wait for treatable symptoms. To achieve this goal, vasodilators, particularly ACE inhibitors, now appear to be essential for the treatment of DCM. Digitalis is added unless contraindicated by adverse effects. Diuretics should be used only to relieve congestive symptoms. In the presence of sinus tachycardia or ventricular arrhythmias, beta-blockers are the next choice in our practice. When congestive symptoms or low output state are not controlled with vasodilators, diuretics, and digitalis, inotropic agents are indicated, with or without mechanical assist devices. For severely ill patients unresponsive to maximal medical management, heart transplantation is needed.